Transfusion Medicine Reviews
Volume 22, Issue 1 , Pages 58-69 , January 2008

Transfusion Transmission of Human Prion Diseases

  • Shimian Zou

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Shimian Zou, PhD, Transmissible Diseases Department, Jerome H. Holland Laboratory, American Red Cross Biomedical Services, 15601 Crabbs Branch Way, Rockville, MD 20855.
    • ,
  • Chyang T. Fang
    • ,
  • Lawrence B. Schonberger

References 

  1. Health Protection Agency . 4th case of variant CJD infection associated with blood transfusion. http://www.hpa.org.uk/hpa/news/articles/press_releases/2007/070118_vCJD.htm
  2. Prusiner SB. An introduction to prion biology and diseases. In:  Prusiner SB editors. Prion biology and diseases. ed 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2004;p. 1–87
  3. Will RG, Alpers MP, Dormont D, et al. Infectious and sporadic prion diseases. In:  Prusiner SB editors. Prion biology and diseases. ed 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2004;p. 629–671
  4. Brown P, Preece MA, Will RG. “Friendly fire” in medicine: Hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992;340:24–27
  5. Holman RC, Khan AS, Kent J, et al. Epidemiology of Creutzfeldt-Jakob disease in the United States, 1979-1990: Analysis of national mortality data. Neuroepidemiology. 1995;14:174–181
  6. ElSaadany S, Semenciw R, Ricketts M, et al. Epidemiological study of Creutzfeldt-Jakob disease death certificates in Canada, 1979-2001. Neuroepidemiology. 2005;24:15–21
  7. Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586–1591
  8. Ironside JW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia. 2006;12(Suppl):8–15
  9. Centers for Disease Control and Prevention . Creutzfeldt-Jakob disease deaths and age-adjusted death rate, United States, 1979-2003. http://www.cdc.gov/ncidod/dvrd/cjd/images/CJD7903_annual_rate_slide.pdf
  10. Prusiner SB. Prions. In:  Fields BN,  Knipe DM,  Howley PM, et al. editor. Virology. ed 3. Philadelphia, PA: Lippincott-Raven; 1996;p. 2901–2950
  11. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921–925
  12. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 2006;5:393–398
  13. Goldfarb LG, Cervenakova L, Gajdusek DC. Genetic studies in relation to kuru: an overview. Curr Mol Med. 2004;4:375–384
  14. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century—An acquired human prion disease with very long incubation periods. Lancet. 2006;367:2068–2074
  15. Blajchman MA, Goldman M, Webert KE, et al. Proceedings of a consensus conference: The screening of blood donors for variant CJD. Transfus Med Rev. 2004;18:73–92
  16. Brown P, Cervenakova L. The modern landscape of transfusion-related iatrogenic Creutzfeldt-Jakob disease and blood screening tests. Curr Opin Hematol. 2004;11:351–356
  17. Brown P. Blood infectivity in the transmissible spongiform encephalopathies. In:  Turner ML editors. Creutzfeldt-Jacob disease: Managing the risk of transmission by blood, plasma, and tissues. Bethesda, MD: AABB Press; 2006;p. 95–118
  18. Cervenakova L, Yakovleva O, McKenzie C, et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion. 2003;43:1687–1694
  19. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol. 2002;83:2897–2905
  20. Siso S, Gonzalez L, Houston F, et al. The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion. Blood. 2006;108:745–748
  21. Bons N, Lehmann S, Mestre-Frances N, et al. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion. 2002;42:513–516
  22. Herzog C, Sales N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet. 2004;363:422–428
  23. Herzog C, Riviere J, Lescoutra-Etchegaray N, et al. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol. 2005;79:14339–14345
  24. Mathiason CK, Powers JG, Dahmes SJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science. 2006;314:133–136
  25. Dodd RY, Busch MP. Animal models of bovine spongiform encephalopathy and vCJD infectivity in blood: two swallows do not a summer make. Transfusion. 2002;42:509–512
  26. Cervenakova L, Brown P. Advances in screening test development for transmissible spongiform encephalopathies. Expert Rev Anti Infect Ther. 2004;2:873–880
  27. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science. 2006;313:92–94
  28. Raeber A. Development of rapid blood screening tests for vCJD. Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  29. Soto C. Use of PMCA for biochemical diagnosis of prion diseases. Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  30. Wilson S. The Seprion Separation System: development of a feasible blood screening protocol for abnormal prion protein. Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  31. Perron H. Detection of PrPres in plasma. Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  32. Lohman K. Pronucleon amplified misfolded protein diagnostic assay (AMP-D). Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  33. Peretz D. CHIRON submission to FDA TSE Advisory Committee Meeting. Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory Committee, September 19, 2006, Gaithersburg, MD, USA. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4240S2-index.htm
  34. US Food and Drug Administration . Blood guidances. http://www.fda.gov/cber/blood/bldguid.htm
  35. Ponte ML. Insights into the management of emerging infections: Regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US. PLoS Med. 2006;3:e342
  36. Dodd RY. Bovine spongiform encephalopathy, variant CJD, and blood transfusion: Beefer madness?. Transfusion. 2004;44:628–630
  37. Murphy EL, Connor JD, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion. 2004;44:645–650
  38. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417–421
  39. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang. 2006;91:348
  40. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  41. Wilson K, Ricketts MN. Transfusion transmission of vCJD: A crisis avoided?. Lancet. 2004;364:477–479
  42. Ironside JW, Bishop MT, Connolly K, et al. Variant Creutzfeldt-Jakob disease: Prion protein phenotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ. 2006;332:1186–1188
  43. Health Protection Agency . New case of transfusion-associated variant-CJD. CDR Wkly. 2006;16:2–3
  44. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review study. Vox Sang. 2006;91:221–230
  45. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet. 2006;368:2061–2067
  46. Eurosurveillance editorial office . Fourth case of transfusion-associated vCJD infection in the United Kingdom. Eurosurveillance Wkly Release. 2007;12:http://www.eurosurveillance.org/ew/2007/070118.asp#4
  47. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet. 2004;364:529–531
  48. The National CJD Surveillance Unit . Fourteenth annual report 2005, Creutzfeldt-Jakob disease surveillance in the UK, December 4, 2006. http://www.cjd.ed.ac.uk/report14.htm
  49. Dorsey KA, Zou S, Notari EP, et al. Survival of blood transfusion recipients. Transfusion. 2006;46:13A;[Abstract]
  50. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt-Jakob disease by blood products. Br J Haematol. 2006;132:13–24
  51. Wientjens DP, Davanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: A reanalysis of case-control studies. Neurology. 1996;46:1287–1291
  52. Kondo K, Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: Association with physical injuries. Ann Neurol. 1982;11:377–381
  53. Davanipour Z, Alter M, Sobel E, et al. Creutzfeldt-Jakob disease: Possible medical risk factors. Neurology. 1985;35:1483–1486
  54. Harries-Jones R, Knight R, Will RG, et al. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: A case-control study of potential risk factors. J Neurol Neurosurg Psychiatry. 1988;51:1113–1119
  55. Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5:177–188
  56. Esmonde TFG, Will RG, Slattery JM, et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet. 1993;341:205–207
  57. Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: A case-control study. Lancet. 1999;353:693–697
  58. Zerr I, Brandel JP, Masullo C, et al. European surveillance on Creutzfeldt-Jakob disease: A case-control study for medical risk factors. J Clin Epidemiol. 2000;53:747–754
  59. van Duijn CM, Delasnerie-Laupretre N, Masullo C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet. 1998;351:1081–1085
  60. Ward HJ, Everington D, Croes EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: A case-control study using community controls. Neurology. 2002;59:543–548
  61. AABB . Highlights of transfusion medicine history. www.aabb.org/Content/About_Blood/Highlights_of_Transfusion_Medicine_History/
  62. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion. 1995;35:802–812
  63. Holman RC, Khan AS, Belay ED, et al. Creutzfeldt-Jakob disease in the United States, 1979-1994: Using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis. 1996;2:333–337
  64. Sullivan MT, Schonberger LB, Kessler D, et al. Creutzfeldt-Jakob disease (CJD) investigational lookback study. Transfusion. 1997;37(Suppl):2S;(abstr)
  65. Evatt B, Austin H, Barnhart E, et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion. 1998;38:817–820
  66. Gibbons RV, Holman RC, Delay ED, et al. Creutzfeldt-Jakob disease in the United States: 1979-1998. JAMA. 2000;284:2322–2323
  67. Zou S, Notari EP, Fujii K, et al. An update on the Creutzfeldt-Jakob disease look back study. Transfusion. 2005;45:32A;(abstr)
  68. Dorsey KA, Zou S, Notari EP, et al. Creutzfeldt-Jakob disease look-back study: An update. Vox Sang. 2006;91:68–69(abstr)
  69. Dorsey KA, Zou S, Notari EP, et al. Creutzfeldt-Jakob disease look-back study: An update. Transfusion. 2006;46:38A;(abstr)
  70. Brown P, Brandel JP, Preese M, et al. Iatrogenic Creutzfeldt-Jakob disease, the waning of an era.. Neurology. 2006;67:389–393

 The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency.

PII: S0887-7963(07)00086-7

doi: 10.1016/j.tmrv.2007.09.003

Transfusion Medicine Reviews
Volume 22, Issue 1 , Pages 58-69 , January 2008

Article Tools